{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:44:34Z","timestamp":1790837074611,"version":"4.1.0"},"reference-count":39,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2014,5,15]],"date-time":"2014-05-15T00:00:00Z","timestamp":1400112000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0097482","type":"journal-article","created":{"date-parts":[[2014,5,15]],"date-time":"2014-05-15T20:48:47Z","timestamp":1400186927000},"page":"e97482","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":71,"title":["Efficacy of Initial Antiretroviral Therapy for HIV-1 Infection in Adults: A Systematic Review and Meta-Analysis of 114 Studies with up to 144 Weeks' Follow-Up"],"prefix":"10.1371","volume":"9","author":[{"given":"Frederick J.","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janaki","family":"Amin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Carr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2014,5,15]]},"reference":[{"key":"ref1","unstructured":"Department of Health and Human Services (DHHS) Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Rockville, Maryland, USA: Department of Health and Human Services; 2013 (updated February 12)."},{"key":"ref2","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1086\/605024","article-title":"Virological response to initial antiretroviral regimens containing abacavir or tenofovir","volume":"200","author":"L Bansi","year":"2009","journal-title":"J Infect Dis"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1097\/01.aids.0000247578.08449.ff","article-title":"An updated systematic overview of triple combination therapy in antiretroviral-naive HIV-infected adults","volume":"20","author":"JA Bartlett","year":"2006","journal-title":"AIDS"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1097\/QAD.0b013e32831db232","article-title":"Efficacy and tolerability of initial antiretroviral therapy: a systematic review","volume":"23","author":"A Carr","year":"2009","journal-title":"AIDS"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Mbuagbaw LC, Irlam JH, Spaulding A, Rutherford GW, Siegfried N (2010) Efavirenz or nevirapine in three-drug combination therapy with two nucleoside-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naive individuals. Cochrane Database Syst Rev: CD004246.","DOI":"10.1002\/14651858.CD004246.pub3"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1093\/jac\/dkr478","article-title":"Very late initiation of HAART impairs treatment response at 48 and 96 weeks: results from a meta-analysis of randomized clinical trials","volume":"67","author":"JA Perez-Molina","year":"2012","journal-title":"Journal Antimicrob Chemother"},{"key":"ref7","volume":"151","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med <volume>151<\/volume>: : 264\u2013269, W264."},{"key":"ref8","unstructured":"Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach - 2013 revision. Geneva, Switzerland: World Health Organization; 2013."},{"key":"ref9","unstructured":"European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of HIV-infected adults, Version 6.1. Paris, France: European AIDS Clinical Society; 2012."},{"key":"ref10","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1097\/QAI.0b013e31824d006e","article-title":"Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: pooled results from the phase 3 double-blind randomized ECHO and THRIVE Trials","volume":"60","author":"CJ Cohen","year":"2012","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/1758-2652-13-S4-P58","article-title":"A comparison of the FDA TLOVR and FDA Snapshot algorithms based on studies evaluating once-daily vs. twice daily lopinavir\/ritonavir (LPV\/r) regimens","volume":"13","author":"R Qaqish","year":"2010","journal-title":"J Int AIDS Soc"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"JP Higgins","year":"2002","journal-title":"Stat Med"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1097\/QAD.0b013e32835cb997","article-title":"Durability of first ART regimen and risk factors for modification, interruption or death in HIV-positive patients starting ART in Europe and N.America 2002-2009","volume":"27","author":"S Abgrall","year":"2013","journal-title":"AIDS"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1097\/QAD.0b013e32835e163d","article-title":"Currently available medications in resource-rich settings may not be sufficient for lifelong treatment of HIV","volume":"27","author":"J Jansson","year":"2013","journal-title":"AIDS"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1001\/jama.2012.7961","article-title":"Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel","volume":"308","author":"MA Thompson","year":"2012","journal-title":"JAMA"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0140-6736(02)09411-4","article-title":"Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies","volume":"360","author":"M Egger","year":"2002","journal-title":"Lancet"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1056\/NEJMoa0906768","article-title":"Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy","volume":"361","author":"PE Sax","year":"2009","journal-title":"New Engl J Med"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/hiv.12004","article-title":"Impact of baseline HIV-1 RNA levels on initial highly active antiretroviral therapy outcome: a meta-analysis of 12,370 patients in 21 clinical trials","volume":"14","author":"C Stephan","year":"2013","journal-title":"HIV Med"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S0140-6736(02)07873-X","article-title":"Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir","volume":"359","author":"S Mallal","year":"2002","journal-title":"Lancet"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/S0140-6736(02)08158-8","article-title":"Genetic variations in HLA-B region and hypersensitivity reactions to abacavir","volume":"359","author":"S Hetherington","year":"2002","journal-title":"Lancet"},{"key":"ref21","unstructured":"Department of Health and Human Services (DHHS) Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Rockville, Maryland, USA: Department of Health and Human Services; 2007 (updated December 1)."},{"key":"ref22","unstructured":"Department of Health and Human Services (DHHS) Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Rockville, Maryland, USA: Department of Health and Human Services; 2012 (updated March 27)."},{"key":"ref23","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0149-2918(02)85132-3","article-title":"Risk factor analysis of hypersensitivity reactions to abacavir","volume":"24","author":"W Symonds","year":"2002","journal-title":"Clin Ther"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1128\/AAC.38.6.1230","article-title":"Intracellular metabolism of (\u2212)- and (+)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine in HepG2 derivative 2.2.15 (subclone P5A) cells","volume":"38","author":"MT Paff","year":"1994","journal-title":"Antimicrob Agents Chemother"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"13938","DOI":"10.1016\/S0021-9258(19)49660-9","article-title":"Deoxycytidine deaminase-resistant stereoisomer is the active form of (+\/\u2212)-2\u2032,3\u2032-dideoxy-3\u2032-thiacytidine in the inhibition of hepatitis B virus replication","volume":"267","author":"CN Chang","year":"1992","journal-title":"J Biol Chem"},{"key":"ref26","unstructured":"Technical update on treatment optimization. Pharmacological equivalence and clinical interchangeability of lamivudine and emtricitabine: a review of current literature. Geneva, Switzerland: World Health Organization; 2012."},{"key":"ref27","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1089\/aid.2004.20.1173","article-title":"Pharmacokinetic and pharmacodynamic characteristics of emtricitabine support its once daily dosing for the treatment of HIV infection","volume":"20","author":"LH Wang","year":"2004","journal-title":"AIDS Res Hum Retroviruses"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1128\/AAC.48.1.176-182.2004","article-title":"Equivalent steady-state pharmacokinetics of lamivudine in plasma and lamivudine triphosphate within cells following administration of lamivudine at 300 milligrams once daily and 150 milligrams twice daily","volume":"48","author":"GJ Yuen","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/QAI.0b013e3181dd911e","article-title":"Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir\/lamivudine versus tenofovir\/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT study","volume":"55","author":"FA Post","year":"2010","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref30","unstructured":"Department of Health and Human Services (DHHS) Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Rockville, Maryland, USA: Department of Health and Human Services; 2006 (updated May 4)."},{"key":"ref31","doi-asserted-by":"crossref","first-page":"e52562","DOI":"10.1371\/journal.pone.0052562","article-title":"Clinical use of HIV integrase inhibitors: a systematic review and meta-analysis","volume":"8","author":"P Messiaen","year":"2013","journal-title":"PLoS One"},{"key":"ref32","unstructured":"Department of Health and Human Services (DHHS) Panel on Antiretroviral Guidelines for Adults and Adolescents. Recommendation on Integrase Inhibitor Use in Antiretroviral Treatment-Naive HIV-Infected Individuals from the HHS Panel on Antiretroviral Guidelines for Adults and Adolescents; 2013 (October 30) [Accessed January 17, 2014 at <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/aidsinfo.nih.gov\/contentfiles\/upload\/AdultARV_INSTIRecommendations.pdf\" xlink:type=\"simple\">http:\/\/aidsinfo.nih.gov\/contentfiles\/upload\/AdultARV_INSTIRecommendations.pdf<\/ext-link>]."},{"key":"ref33","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1097\/00126334-200408150-00003","article-title":"Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV","volume":"36","author":"K Squires","year":"2004","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1310\/hct1102-69","article-title":"Safety and efficacy of a 36-week induction regimen of abacavir\/lamivudine and ritonavir-boosted atazanavir in HIV-infected patients","volume":"11","author":"KE Squires","year":"2010","journal-title":"HIV Clin Trials"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"e1001290","DOI":"10.1371\/journal.pmed.1001290","article-title":"Efficacy and safety of three antiretroviral regimens for initial treatment of HIV-1: a randomized clinical trial in diverse multinational settings","volume":"9","author":"TB Campbell","year":"2012","journal-title":"PLoS Med"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1086\/420932","article-title":"Atazanavir: new option for treatment of HIV infection","volume":"38","author":"DV Havlir","year":"2004","journal-title":"Clin Infect Dis"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/QAI.0b013e318263277e","article-title":"Sustained efficacy and safety of raltegravir after 5 years of combination antiretroviral therapy as initial treatment of HIV-1 infection: final results of a randomized, controlled, phase II study (Protocol 004)","volume":"61","author":"E Gotuzzo","year":"2012","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/QAI.0b013e31828ace69","article-title":"Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir\/emtricitabine in treatment-naive HIV-1-infected patients: final 5-year results from STARTMRK","volume":"63","author":"JK Rockstroh","year":"2013","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1097\/QAD.0b013e3283612419","article-title":"Dolutegravir in antiretroviral-naive adults with HIV-1: 96-week results from a randomized dose-ranging study","volume":"27","author":"HJ Stellbrink","year":"2013","journal-title":"AIDS"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0097482","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,3]],"date-time":"2022-04-03T17:16:32Z","timestamp":1649006192000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0097482"}},"subtitle":[],"editor":[{"given":"Mark","family":"Wainberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2014,5,15]]},"references-count":39,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2014,5,15]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0097482","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,5,15]]}}}